The results position Hengrui to seek approval of the Zepbound-like drug in China and Kailera, a well-funded biotech startup, ...

Sino Biopharmaceuticals plans to pay up to nearly $951 million to acquire LaNova Medicines, which previously licensed drugs ...

The CDMO, which has been owned by different private investors over the last decade, will use the funds to broaden its ...

NHS England has agreed to reimburse Vertex's newest cystic fibrosis medicine. Meanwhile, Merck advanced its once-monthly PrEP ...

Baxdrostat, which AstraZeneca acquired in a 2023 buyout of CinCor Pharma, could become a new treatment for people whose ...

Positive late-stage study results position the company to file for clearance of what could be the first narcolepsy drug that ...

The complaint argues Kennedy’s actions to remove the COVID vaccine from the CDC's immunization schedule for pregnant people ...

One analyst described Cogent’s data as a “home run scenario” for bezuclastinib, which the company is positioning as a ...

Current operations chief Renee Gala will succeed Bruce Cozadd at Jazz. Meanwhile, a key study of an Ultragenyx and Mereo drug ...

Coartem Baby, which was cleared by health authorities in Switzerland, will fill an important gap in treatment. Novartis plans ...

Company executives had seen the drug as a potential multi-billion dollar opportunity in women’s health.

The cell therapy developer, which raised nearly $500 million in 2023 on the promise of its CAR-T work, has floundered since a ...